St. Jude Authorizes Share Repurchase

Zacks

St. Jude Medical Inc. (STJ) revealed that its board of directors authorized a share repurchase worth up to $700 million of its outstanding common stock. The Saint Paul, Minn.-based leading medical device maker last authorized a share repurchase program on Nov 29, 2012.

Under the previous share repurchase program, STJ authorized the repurchase of shares worth up to $1.0 billion and began repurchasing shares on Dec 5, 2012. The company has completed the repurchase program on Feb 5, 2013, repurchasing 13.9 million shares for $542 million, reflecting an average price of $38.83.

Since 2010, St. Jude Medical has repurchased shares worth $3.0 billion. As of Dec 6, 2013, STJ had roughly 292 million issued and outstanding shares.

St. Jude Medical, a Zacks Rank #3 (Hold) company, posted third-quarter adjusted earnings per share of 90 cents, beating the Zacks Consensus Estimate by a penny. Third quarter earnings also surpassed the year-ago earnings of 83 cents by 8.4%. Adjusted earnings were at the higher end of the company’s third-quarter guidance of 88–90 cents a share.

Revenues inched up 1% (3% in constant currency) year over year to $1,338 million in the third quarter and exceeded the Zacks Consensus Estimate of $1,321 million. Unfavorable foreign currency lowered total revenues by $26 million. Revenues in the U.S. (48.3% of total revenues) and in the international markets (51.7%) increased 1.1% and 0.7% to $646 million and $692 million, respectively in the reported quarter.

STJ expects total revenues in the range of $5,394 to $5,474 million for full year 2013. Further, the company upgraded its adjusted earnings expectations for the year to the band of $3.72–$3.74 from the earlier range of $3.70–$3.73. The current Zacks Consensus Estimate for 2013 revenues and earnings are pegged at $5,455 million and $3.73 per share.

For the fourth quarter, St. Jude anticipates revenues in the range of $1,315 to $1,395 million and adjusted earnings between 95 and 97 cents a share. The Zacks Consensus Estimate for revenues and earnings for the fourth quarter stands at $1,376 million and 96 cents per share, respectively.

Other better-ranked medical product stocks that currently worth a look include Bio-Rad Laboratories, Inc. (BIO), Hill-Rom Holdings, Inc. (HRC), and NuVasive, Inc. (NUVA). While Bio-Rad Laboratories and Hill-Rom Holdings carry a Zacks Rank #1 (Strong Buy), NuVasive carries a Zacks Rank #2 (Buy).

Read the Full Research Report on STJ
Read the Full Research Report on NUVA
Read the Full Research Report on HRC
Read the Full Research Report on BIO


Zacks Investment Research

View Comments (0)